TICKERNOMICS Sign up
Last Update: 2024-12-27 15:25:58
Akebia Therapeutics Inc. ( AKBA ) https://www.akebia.com
1.93USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
AKBA
50.78%
SPY
32.66%
-15.35%
AKBA
SPY
108.59%
-70.40%
AKBA
SPY
302.52%
-83.38%
AKBA
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
389.14
436.77
1.66
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-8.46
2.32
-7.72
-13.91
0.00
-39.21
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-35.13
85.53
-7.55
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.0
-43.83
-26.43
1.00
Other Earnings and Cash Flow Stats:
Akebia Therapeutics Inc. ( AKBA ) Net Income TTM ($MM) is -45.99
Akebia Therapeutics Inc. ( AKBA ) Operating Income TTM ($MM) is -34.79
Akebia Therapeutics Inc. ( AKBA ) Owners' Earnings Annual ($MM) is 0.00
Akebia Therapeutics Inc. ( AKBA ) Current Price to Owners' Earnings ratio is 0.00
Akebia Therapeutics Inc. ( AKBA ) EBITDA TTM ($MM) is 8.21
Akebia Therapeutics Inc. ( AKBA ) EBITDA Margin is -7.55%
Capital Allocation:
Akebia Therapeutics Inc. ( AKBA ) has paid 0.00 dividends per share and bought back -22.042109 million shares in the past 12 months
Akebia Therapeutics Inc. ( AKBA ) has increased its debt by 19.085 million USD in the last 12 months
Capital Structure:
Akebia Therapeutics Inc. ( AKBA ) Interest-bearing Debt ($MM) as of last quarter is 81
Akebia Therapeutics Inc. ( AKBA ) Annual Working Capital Investments ($MM) are -30
Akebia Therapeutics Inc. ( AKBA ) Book Value ($MM) as of last quarter is -51
Akebia Therapeutics Inc. ( AKBA ) Debt/Capital as of last quarter is -162%
Other Balance Sheet Stats:
Akebia Therapeutics Inc. ( AKBA ) has 34 million in cash on hand as of last quarter
Akebia Therapeutics Inc. ( AKBA ) has 65 million of liabilities due within 12 months, and long term debt 55 as of last quarter
Akebia Therapeutics Inc. ( AKBA ) has 210 common shares outstanding as of last quarter
Akebia Therapeutics Inc. ( AKBA ) has 0 million USD of preferred stock value
Academic Scores:
Akebia Therapeutics Inc. ( AKBA ) Altman Z-Score is -10.15 as of last quarter
Akebia Therapeutics Inc. ( AKBA ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Akebia Therapeutics Inc. ( AKBA ) largest shareholder is owning shares at 0.00 ($MM) value
Hadas Nicole R.(an insider) Sold 12016 shares of Akebia Therapeutics Inc. ( AKBA ) for the amount of $15140.16 on 2024-05-13
2.09% of Akebia Therapeutics Inc. ( AKBA ) is held by insiders, and 25.88% is held by institutions
Akebia Therapeutics Inc. ( AKBA ) went public on 2014-03-20
Other Akebia Therapeutics Inc. ( AKBA ) financial metrics:
FCF:-38.67
Unlevered Free Cash Flow:0.00
EPS:-0.38
Operating Margin:-35.13
Gross Profit Margin:85.53
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:159.03
Beta:1.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Akebia Therapeutics Inc. ( AKBA ) :
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.